Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7249139 | 1.00 | NPSR1 (0.55) | NPSR1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL7437764 | 0.82 | CCNC (0.43) | NPSR1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL7437761 | 0.82 | CCNC (0.43) | NPSR1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL7442946 | 0.79 | NPSR1 (0.39) | NPSR1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL7442942 | 0.79 | NPSR1 (0.39) | NPSR1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL7441294 | 0.78 | NPSR1 (0.39) | NPSR1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL7430603 | 0.77 | NPSR1 (0.38) | NPSR1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL7437153 | 0.76 | LMNA (0.38) | NPSR1KDM4ELMNAALDH1A1POLB | |
| SCHEMBL7437156 | 0.76 | LMNA (0.38) | NPSR1KDM4ELMNAALDH1A1POLB | |
| SCHEMBL18533472 | 0.76 | NPSR1 (0.50) | NPSR1MEN1KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TST, STS, AHR | NPSR1 857/4885MEN1 3625/4885KMT2A 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.